Books
in black and white
Main menu
Share a book About us Home
Books
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics
Ads

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 211 212 213 214 215 216 < 217 > 218 219 220 221 222 223 .. 292 >> Next

Legaz, M. et al. (1973). Isolation and characterization of human factor VIII (antihaemophilic factor). J. Biol. Chem. 248, 3946-3955.
Nicholson, J. et al. (2000). The role of albumin in critical illness. Br. J. Anaesth. 85(4), 599-610.
Ogden, J. (1992). Recombinant haemoglobin in the development of red blood cell substitutes. Trends in Biotech. 10, 91-95.
Winslow, R. (2000). Blood substitutes: refocusing an elusive goal. Br. J. Haematol. 111(2), 387-396.
Wright, G. et al. (1991). High level expression of active human a-1-antitrypsin in the milk of transgenic sheep. Bio/ Technology 9, 830-834.
Anticoagulants and related substances
Dodt, J. (1995). Anti-coagulatory substances of bloodsucking animals: from hirudin to hirudin mimetics. Angew. Chem.
Int. Ed. Engl. 34, 867-880.
Eldora, A. et al. (1996). The role of the leech in medical therapeutics. Blood Rev. 10(4), 201-209.
Fitzgerald, G. (1996). The human pharmacology of thrombin inhibition. Coronary Artery Dis. 7(12), 911-918. Markwardt, F. (1991). Hirudin and its derivatives as anticoagulant agents. Thromb. Haemost. 66, 141-152.
Pineo, G. & Hull, R. (1997). Low molecular weight heparin—prophylaxis and treatment of venous thromboembolism.
Ann. Rev. Med. 48, 79-91.
Salzet, M. (2002). Leech thrombin inhibitors. Curr. Pharmaceut. Design 8(7), 493-503.
Sawyer, R. (1991). Thrombolytics and anticoagulants from leeches. Bio/Technology 9, 513-518.
Schulman, S. (1996). Anticoagulation in venous thrombosis. J. R. Soc. Med. 89(11), 624-630.
Sohn, J. et al. (2001). Current status of the anticoagulant hirudin: its biotechnological production and clinical practice.
Appl. Microbiol. Biotechnol. 57(5-6), 606-613.
Tencate, H. et al. (1996). Developments in anti-thrombolic therapy—state of the art, anno 1996. Pharmacy World Sci. 18(6), 195-203.
Walker, C & Royston, D. (2002). Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br. J. Anaesth. 88(6), 848-863.
Thrombolytics
Al-Buhairi, A. & Jan, M. (2002). Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Med. J. 23(1), 13-19.
Blasi, F. (1999). The urokinase receptor. A cell surface, regulated chemokine. APMIS 107(1), 96-101.
Castillo, P. et al. (1997). Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Ann. Pharmacother. 31(5), 596-603.
Collen, D. & Lijnen, H. (1994). Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 84(3), 680-686.
Collen, D. (1998). Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Med. 4(3), 279-284. Collins, R. et al. (1997). Drug therapy—aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N. Engl. J. Med. 336(12), 847-860.
Datar, R. et al. (1993). Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator. Bio/Technology 11, 349-357.
Emeis, J. et al. (1997). Progress in clinical fibrinolysis. Fibrinolysis Proteolysis 11(2), 67-84.
402 BIOPHARMACEUTICALS
Gillis, J. et al. (1995). Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 50(1), 102-136.
Marder, V. & Stewart, D. (2002). Towards safer thrombolytic therapy. Semin. Haematol. 39(3), 206-216.
Preissner, K. et al. (2000). Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell Biol. 12(5), 621-628.
Rabasseda, X. (2001). Tenecteplase (TNK tissue plasminogen activator): a new fibrinolytic for the acute treatment of myocardial infarction. Drugs Today 37(11), 749-760.
Schoebel, F. et al. (1997). Antithrombotic treatment in stable coronary syndromes—long-term intermittent urokinase therapy in end-stage coronary-artery disease and refractory angina pectoris. Heart 77(1), 13-17.
Tsirka, S. (1997). Clinical implications of the involvement of tPA in neuronal cell death. J. Mol. Med. 75(5), 341-347.
Verstraete, M. et al. (1995). Thrombolytic agents in development. Drugs, 50(1), 29-42.
Verstraete, M. (2000). Third generation thrombolyic drugs. Am. J. Med. 109(1), 52-58.
Enzyme therapeutics
Barranger, J. et al. (1995). Molecular biology of glucocerebrosidase and the treatment of Gaucher’s disease. Cytokines Mol. Ther. 1(3), 149-163.
Chakrabarti, R. & Schuster, S. (1997). L-Asparaginase—perspectives on the mechanisms of action and resistance. Int. J.
Pediat. Haematol./Oncol. 4(6), 597-611.
Chapple, L. (1997). Reactive oxygen species and antioxidants in inflammatory diseases. J. Clin. Periodontol. 24(5), 287-296.
Conway, S. & Littlewood, J. (1997). rhDNase in cystic fibrosis. Br. J. Hosp. Med. 57(8), 371-372.
Conway, S. & Watson, A. (1997). Nebulized bronchodilators, corticosteroids and rhDNase in adult patients with cystic fibrosis. Thorax 52(2), S64-S68.
Edgington, S. (1993). Nuclease therapeutics in the clinic. Bio/Technology 11, 580-582.
Previous << 1 .. 211 212 213 214 215 216 < 217 > 218 219 220 221 222 223 .. 292 >> Next